RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 15 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 15

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  2. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  3. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  4. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  5. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  6. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  7. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  8. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  9. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  10. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  11. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
  12. Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
  13. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  14. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  15. Study siteZhongda Hospital, Southeast University东南大学附属中大医院NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07164170, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).

    Inclusion criterion 3

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.

    Inclusion criterion 10

  4. Patients must have at least one measurable lesion as defined by RECIST v1.1.

    Inclusion criterion 9

  5. Histological or cytological evidence of small cell lung cancer or neuroendocrine carcinoma components.

    Exclusion criterion 1

    Has a known human immunodeficiency virus (HIV) infection that is not well controlled.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07164170, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Prior to any protocol- specific procedures are performed, the patient should understand and voluntarily sign and date the written informed consent form.
  • Gender was not limited patients aged ≥18 years at the time of signing the informed consent.
  • Histologically or cytologically confirmed locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).

For patients in the dose-escalation cohort (Part A) of the escalation part:

Patients must have experienced disease progression following at least one line of prior standard systemic therapy, but no more than two lines of systemic therapy.

For patients in the dose confirmation cohort (Part B) of the escalation part :

  • Prior treatment requirements for patients in cohort (Part B) are the same as those for patients in (Part A);
  • Documented or central laboratory test report confirmed that the tumor was PD-L1 expression positive (≥1%) .

For patients in the expansion cohort of the expansion part :

  • Patients who have not received prior systemic therapy for locally advanced or unresectable/metastatic disease;
  • Central laboratory test report confirmed that the tumor was PD-L1 expression positive (≥1%) .
  • Tumor tissue or blood test report confirmed KRASG12C mutation.
  • Patients must have at least one measurable lesion as defined by RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
  • Expected survival time of ≥3 months.
  • Patients must have adequate organ and bone marrow function.

Exclusion Criteria:

  • Histological or cytological evidence of small cell lung cancer or neuroendocrine carcinoma components.
  • Toxicities from prior antitumor therapy have not returned to baseline or stabilized.
  • Patients with active brain metastases.
  • The patient currently has active interstitial lung disease.
  • Patients currently have active autoimmune disease or a history of autoimmune disease that may be at risk for recurrence.
  • Any condition requiring systemic treatment with corticosteroids.
  • Uncontrolled or significant cardiovascular disease.
  • Has a known human immunodeficiency virus (HIV) infection that is not well controlled.
  • Any evidence of severe or uncontrolled diseases or other factors which in the Investigator's opinion makes it undesirable for the patients to participate in the study

Quoted from ClinicalTrials.gov, NCT07164170, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07164170, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07164170